Generic Name and Formulations:
Chloroprocaine HCl 20mg/mL, 30mg/mL; soln for inj; preservative-free.
Fresenius Kabi USA
Indications for NESACAINE-MPF:
Production of local anesthesia by infiltration, peripheral and central nerve block, including lumbar and caudal epidural blocks.
Epidural anesthesia: administer test dose first; monitor for CNS or cardiovascular toxicity. See literature for dosing based on procedure. Individualize. Max single recommended dose: 11mg/kg, not to exceed max total dose of 800mg. Debilitated, elderly, acutely ill (cardiac and/or liver disease): reduce dose.
<3yrs: see literature. Individualize based on age and weight. ≥3yrs: max 11mg/kg.
Not for subarachnoid administration. Lumbar and caudal epidural anesthesia: caution with existing neurological disease, spinal deformities, septicemia, severe hypertension. To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Hypotension. Heart block. Monitor cardiovascular and respiratory vital signs. Hepatic impairment. Retrobulbar block. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Concomitant sulfonamides: not recommended.
CNS effects (eg, excitation, depression, restlessness, anxiety, dizziness, tremors), cardiovascular effects (eg, myocardium depression, decreased cardiac output, heart block, hypotension, bradycardia, ventricular arrhythmias, cardiac arrest), allergic-type reactions, neurologic effects (eg, spinal block, urinary retention, paresthesia, weakness, headache, paralysis of lower extremities).
Nesacaine: Multi-dose vial (30mL)—1; Nesacaine-MPF: Single-dose vial (20mL)—1
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Prediabetes a Useful Indicator for Cardiovascular and Renal Risks